title: New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.
authors.affiliation: CVS Health, Woonsocket, Rhode Island.
authors.forename: William H
authors.initials: WH
authors.lastname: Shrank
authors.affiliation: CVS Health, Woonsocket, Rhode Island.
authors.forename: Jane F
authors.initials: JF
authors.lastname: Barlow
authors.affiliation: CVS Health, Woonsocket, Rhode Island.
authors.forename: Troyen A
authors.initials: TA
authors.lastname: Brennan
mesh_terms: D008078:Cholesterol, LDL / Q000097:blood*; D016527:Drug Costs; D005060:Europe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000191:economics / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases; D014481:United States
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases